These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 15829405

  • 1. G-CSF treatment prevents cyclophosphamide acceleration of autoimmune diabetes in the NOD mouse.
    Hadaya K, Kared H, Masson A, Chatenoud L, Zavala F.
    J Autoimmun; 2005 Mar; 24(2):125-34. PubMed ID: 15829405
    [Abstract] [Full Text] [Related]

  • 2. BCG vaccination prevents insulin-dependent diabetes mellitus (IDDM) in NOD mice after disease acceleration with cyclophosphamide.
    Qin HY, Singh B.
    J Autoimmun; 1997 Jun; 10(3):271-8. PubMed ID: 9218754
    [Abstract] [Full Text] [Related]

  • 3. Acceleration of autoimmune diabetes by cyclophosphamide is associated with an enhanced IFN-gamma secretion pathway.
    Ablamunits V, Quintana F, Reshef T, Elias D, Cohen IR.
    J Autoimmun; 1999 Dec; 13(4):383-92. PubMed ID: 10585754
    [Abstract] [Full Text] [Related]

  • 4. In vivo blockade of the Fas-Fas ligand pathway inhibits cyclophosphamide-induced diabetes in NOD mice.
    Mahiou J, Walter U, Lepault F, Godeau F, Bach JF, Chatenoud L.
    J Autoimmun; 2001 Jun; 16(4):431-40. PubMed ID: 11437491
    [Abstract] [Full Text] [Related]

  • 5. Nicotinamide prevents the development of diabetes in the cyclophosphamide-induced NOD mouse model by reducing beta-cell apoptosis.
    O'Brien BA, Harmon BV, Cameron DP, Allan DJ.
    J Pathol; 2000 May; 191(1):86-92. PubMed ID: 10767724
    [Abstract] [Full Text] [Related]

  • 6. Dissimilar background genes control susceptibility to autoimmune disease in the context of different MHC haplotypes: NOD.H-2(s) congenic mice are relatively resistant to both experimental autoimmune encephalomyelitis and type I diabetes.
    Greve B, Reddy J, Waldner HP, Sobel RA, Kuchroo VK.
    Eur J Immunol; 2004 Jul; 34(7):1828-38. PubMed ID: 15214031
    [Abstract] [Full Text] [Related]

  • 7. Analysis of action mechanism of lymphotoxin in prevention of cyclophosphamide-induced diabetes in NOD mice.
    Takahashi K, Satoh J, Sagara M, Zhu XP, Muto G, Muto Y, Fukuzawa M, Nishimura S, Miyaguchi S, Toyata T.
    J Autoimmun; 1995 Jun; 8(3):335-46. PubMed ID: 7575995
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Deficiency in NOD antigen-presenting cell function may be responsible for suboptimal CD4+CD25+ T-cell-mediated regulation and type 1 diabetes development in NOD mice.
    Alard P, Manirarora JN, Parnell SA, Hudkins JL, Clark SL, Kosiewicz MM.
    Diabetes; 2006 Jul; 55(7):2098-105. PubMed ID: 16804081
    [Abstract] [Full Text] [Related]

  • 14. CD4+CD25+ regulatory T cells control the progression from periinsulitis to destructive insulitis in murine autoimmune diabetes.
    Ott PA, Anderson MR, Tary-Lehmann M, Lehmann PV.
    Cell Immunol; 2005 May; 235(1):1-11. PubMed ID: 16122720
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Immunolocalization of monocyte chemoattractant protein-1 in islets of NOD mice during cyclophosphamide administration.
    Reddy S, Bai Y, Robinson E, Ross J.
    Ann N Y Acad Sci; 2006 Oct; 1079():103-8. PubMed ID: 17130538
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Control of type 1 autoimmune diabetes by naturally occurring CD4+CD25+ regulatory T lymphocytes in neonatal NOD mice.
    Piccirillo CA, Tritt M, Sgouroudis E, Albanese A, Pyzik M, Hay V.
    Ann N Y Acad Sci; 2005 Jun; 1051():72-87. PubMed ID: 16126946
    [Abstract] [Full Text] [Related]

  • 19. Transient chemokine receptor blockade does not prevent, but may accelerate type 1 diabetes in prediabetic NOD mice.
    Seifarth C, Mack M, Steinlicht S, Hahn EG, Lohmann T.
    Horm Metab Res; 2006 Mar; 38(3):167-71. PubMed ID: 16673207
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.